Autopsy report · NCT03145909

A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

Cause of deathSafety Automatic label, confidence 0.9, unverified. How labels are made.

“Safety”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 1 year 5 months before it stopped.
19 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: AbbVie
Sponsor type: Industry
Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-176
Participants: 19
Sites: 11
Countries: Australia, Denmark, Spain, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.